Top

Published in:

01-07-2011 | Brief report

Telomere length in peripheral blood and breast cancer risk in a prospective case-cohort analysis: results from the Sister Study

Authors: Sangmi Kim, Dale P. Sandler, Gleta Carswell, Lisa A. De Roo, Christine G. Parks, Richard Cawthon, Clarice R. Weinberg, Jack A. Taylor

Published in: Cancer Causes & Control | Issue 7/2011

Abstract

Objective

Telomeres are required for maintaining genomic integrity and may play a role in carcinogenesis. Some, but not all, epidemiologic studies have found that short telomeres in leukocytes are associated with an increased risk of breast cancer. To further elucidate this potential association, we examined telomere length in relation to breast cancer risk in prospectively collected blood samples from the Sister Study, a cohort of women aged 35–74 years who have a sister with breast cancer.

Methods

We performed a case-cohort analysis comparing incident breast cancer cases (n = 342) with a subcohort (n = 735), randomly selected from 29,026 participants, enrolled by June 1, 2007. Relative telomere length in peripheral blood cells was estimated using a single-tube monochrome multiplex quantitative PCR assay.

Results

No association was observed between telomere length and breast cancer risk. Compared with the longest quartile, hazard ratios (HR) associated with the second, third, and the shortest quartile were 0.91 [95% confidence interval (95% CI): 0.62–1.34], 1.11 (95% CI: 0.77–1.60), and 0.93 (95% CI: 0.64–1.35), respectively. Subgroup analyses by menopausal status, invasiveness, or estrogen receptor status of breast cancer did not reveal evidence of association between telomere length in blood cells and subsequent breast cancer risk.

Conclusions

This prospective investigation does not support telomere length in blood cells as a biomarker for breast cancer risk.

Monaghan P, Haussmann MF (2006) Do telomere dynamics link lifestyle and lifespan? Trends Ecol Evol 21(1):47–53PubMedCrossRef

Meeker AK, Hicks JL, Gabrielson E, Strauss WM, De Marzo AM, Argani P (2004) Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol 164(3):925–935PubMedCrossRef

Cheung AL, Deng W (2008) Telomere dysfunction, genome instability and cancer. Front Biosci 13:2075–2090PubMedCrossRef

Sharpless NE, DePinho RA (2004) Telomeres, stem cells, senescence, and cancer. J Clin Invest 113(2):160–168PubMed

Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG et al (2004) In situ analyses of genome instability in breast cancer. Nat Genet 36(9):984–988PubMedCrossRef

Levy T, Agoulnik I, Atkinson EN, Tong XW, Gause HM, Hasenburg A et al (1998) Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients. Anticancer Res 18(3A):1345–1349PubMed

Pooley KA, Sandhu MS, Tyrer J, Shah M, Driver KE, Luben RN et al (2010) Telomere length in prospective and retrospective cancer case–control studies. Cancer Res 70(8):3170–3176PubMedCrossRef

Shen J, Gammon MD, Terry MB, Wang Q, Bradshaw P, Teitelbaum SL et al (2009) Telomere length, oxidative damage, antioxidants and breast cancer risk. Int J Cancer 124(7):1637–1643PubMedCrossRef

10.

Svenson U, Nordfjall K, Stegmayr B, Manjer J, Nilsson P, Tavelin B et al (2008) Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res 68(10):3618–3623PubMedCrossRef

11.

Gramatges MM, Telli ML, Balise R, Ford JM (2010) Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. Cancer Epidemiol Biomarkers Prev 19(2):605–613PubMedCrossRef

12.

Zheng YL, Ambrosone C, Byrne C, Davis W, Nesline M, McCann SE (2010) Telomere length in blood cells and breast cancer risk: investigations in two case–control studies. Breast Cancer Res Treat 120(3):769–775

13.

De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ (2009) A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 18(4):1152–1156PubMedCrossRef

14.

Weinberg CR, Shore DL, Umbach DM, Sandler DP (2007) Using risk-based sampling to enrich cohorts for endpoints, genes, and exposures. Am J Epidemiol 166(4):447–455PubMedCrossRef

15.

Cawthon RM (2009) Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 37(3):e21PubMedCrossRef

16.

Prentice RL (1986) A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73(1):1–11CrossRef

17.

Barlow WE, Ichikawa L, Rosner D, Izumi S (1999) Analysis of case-cohort designs. J Clin Epidemiol 52(12):1165–1172PubMedCrossRef

18.

Shen J, Terry MB, Gurvich I, Liao Y, Senie RT, Santella RM (2007) Short telomere length and breast cancer risk: a study in sister sets. Cancer Res 67(11):5538–5544PubMedCrossRef

19.

Schröder CP, Wisman GB, de Jong S, van der Graaf WT, Ruiters MH, Mulder NH et al (2001) Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer 84(10):1348–1353PubMedCrossRef

20.

Mirabello L, Yu K, Kraft P, De Vivo I, Hunter DJ, Prescott J et al (2010) The association of telomere length and genetic variation in telomere biology genes. Hum Mutat 31(9):1050–1058PubMedCrossRef

21.

Cawthon RM (2002) Telomere measurement by quantitative PCR. Nucleic Acids Res 30(10):e47PubMedCrossRef

22.

Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF et al (2005) Obesity, cigarette smoking, and telomere length in women. Lancet 366(9486):662–664PubMedCrossRef

23.

Kim S, Parks CG, DeRoo LA, Chen H, Taylor JA, Cawthon RM et al (2009) Obesity and weight gain in adulthood and telomere length. Cancer Epidemiol Biomarkers Prev 18(3):816–820PubMedCrossRef

Title: Telomere length in peripheral blood and breast cancer risk in a prospective case-cohort analysis: results from the Sister Study
Authors: Sangmi Kim
Dale P. Sandler
Gleta Carswell
Lisa A. De Roo
Christine G. Parks
Richard Cawthon
Clarice R. Weinberg
Jack A. Taylor
Publication date: 01-07-2011
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 7/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-011-9778-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2011

Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype

Adiposity and the risk of colorectal adenomatous polyps: a meta-analysis

Commentary: Serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial

Alcohol and tobacco, and the risk of cancers of the upper aerodigestive tract in Latin America: a case–control study

Erratum to: Abuse victimization and risk of breast cancer in the Black Women’s Health Study

The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series

Keynote webinar | Spotlight on antibody–drug conjugates in cancer